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NeurodegenerationThere is a strong correlation between taupathies and the development and progression of neurodegenerative dis-
orders. Abnormal tau becomes hyperphosphorylated and dissociated frommicrotubules with the aggregation of
intracellular tau aggregates within the patient's brain. The current review is divided into two broad sections. In
the ﬁrst section we discuss the molecular biology and the clinicopathologic features of taupathies. While in the
second section we discuss the relationship between mitochondrial complex-I and taupathies. Polymorphism in
NDUFA12L may be a crucial factor for development of neurodegenerative taupathies. Thus NDUFA12L screening
may be an early biomarker for identifying risk groups for such disorders.
© 2015 Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
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The elderly population is living longer and increasingly struck by
neurodegenerative disorders. Therefore, studying these disorders is in-
creasingly imperative (Denk and Wade-Martins, 2009) particularly,
taupathies (Ludolph et al., 2009). Advances in histo-pathological
techniques improved our understanding of many neurodegenerative
disorders via characterization of the insoluble proteins in neuronal
and glial cells, and taupathies are no exclusion (Goedert, 2004).
Tau is a Micro-tubular Associated Protein (MAP) in the brain. It was
assigned a Greek letter “T” to indicate its ability to assemble tubulin
(Weingarten et al., 1975). It maintains the neural function and transport
of signals through axons and dendrites of neurons (Kovacs, 2015), and
plays an important role in micro-tubular function as it binds to microtu-
bules leading to their assembly and stabilization (Spillantini and
Goedert, 2013). Soluble taumay undergo posttranslationalmodiﬁcations
as hyper phosphorylation and convert to insoluble neuroﬁbrillary taued).
en access article under the CC BY-NC(NFT). Hence, in taupathies, the soluble tau protein disengages from
themicrotubules and forms odd aggregates of tau,which is ubiquitinated
(Kumar Dasappa and Nagendra, 2013; Shiryaev et al., 2009). There are
six isoforms of tau protein expressed by the Micro-tubular Associated
Protein Tau (MAPT) gene located on chromosome 17, so any mutations
in the MAPT gene are associated with fronto-temporal dementia and
Parkinsonism linked to chromosome 17 (FTDP-17MAPT) (Kovacs,
2015). Thus, taupathy is increasingly recognized as a possible contribut-
ing factor in the development of Parkinson's disease (PD) (Spillantini
and Goedert, 2013).
1.1. Molecular biology of taupathies
In normal brains, tau is thought to have important roles in microtu-
bule stabilization and assembly. Moreover, taumay help in signal trans-
duction mechanisms, interactions with the actin cytoskeleton, neurite
outgrowth and stabilization during brain development (Binder et al.,
1985; Kambe et al., 2011). Tau is alternatively spliced in exons 2, 3,
and 10, forming six different tau isoforms. Exon 10 splice products are
particularly prone to mutations, which may affect the aggregation of-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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tau) and three isoformswith fourmicrotubule-binding repeats (4R tau).
While NFTs have historically been considered the main hallmark in
tauopathies, they do not appear to be the main toxic species in disease.
Cell death occurs in disease prior to the formation of NFTs (van de Nes
et al., 2008; Gerson et al., 2014) and NFT-containing neurons have
been shown to be functionally intact in vivo (Kuchibhotla et al., 2014).
Tau animalmodels show all the criteria of the disease i.e. behavioral dis-
turbance and locomotor deterioration without NFT formation (Cowan
et al., 2010). It seems that tau oligomers (the intermediate tau species
that form between tau monomers and NFTS) are responsible for the
onset of disease. Tau oligomer levels have been correlated to the clinical
symptoms in Alzheimer's disease (AD) and Progressive Supra-nuclear
Palsy (PSP) brains (Gerson et al., 2014). Additionally, when administer-
ing tau oligomers to wild-type mice, synaptic and mitochondrial dys-
function as well as cognitive deﬁcits have been observed (Lasagna-
Reeves et al., 2011). The disordered, high energy state of monomeric
tau, when released from binding to microtubules, allows for the expo-
sure of hydrophobic patches and the formation of intermolecular con-
tacts, leading to the mis-folding and aggregation of the tau monomer
in disease. Tau ﬁbrils that comprise NFTs are composed of hyper-
phosphorylated tau in cross β-sheet conformation common to amyloid
ﬁbrils (von Bergen et al., 2005) and take on twomajor forms: paired he-
lical ﬁlaments (PHFs) and straight ﬁlaments. Tau ﬁbrils are capable of
seeding the ﬁbrillization of the tau monomer by template-assisted
growth, whereby monomers that come into contact with the tau ﬁla-
ment are integrated into parallel β-sheet structure (Barghorn and
Mandelkow, 2002; Chirita et al., 2003). Tau oligomers have been further
shown to be the precursors for tau aggregation, through a process called
oligomer-nucleated conformational induction (Lee et al., 2011) in
which the taumonomer is ﬁrst converted to an oligomeric state then ﬁ-
brils are formed. Post-translational modiﬁcations and the formation of
disulﬁde bridges increase the ability of tau to form oligomers (Sahara
et al., 2007). Furthermore, tau oligomers were detected in AD patients'
platelets, suggesting that such tau could serve as a new biological mark-
er for AD (Neumann et al., 2011).
2. Clinico-pathologic patterns of taupathies
Taupathies are the etiological name for certain disorders that
share the same abnormal tau aggregates. Taupathies include nearly
more than 20 different degenerative disorders especially Alzheimer's
disease (AD) and frontotemporal lobar degeneration (FTLD)(Kovacs,
2015; Spillantini and Goedert, 2013; Xie et al., 2014). All these disorders
contain insoluble tau inclusions with cell injury and death (Williams,
2006). FTLD includes frontotemporal dementia with Parkinsonism
linked to chromosome 17 (FTDP-17), Pick's disease (PiD), argyrophilic
grain dementia (AGD), progressive supra-nuclear palsy (PSP), and
corticobasal degeneration (CBD) (Takenokuchi et al., 2010). Further-
more, Parkinson's disease (PD) which is the most frequent cause of
Parkinsonism, is known as α-synucleinopathies as it shows many
Lewy bodies with multiple tau antibodies (Skovronsky, 2007). Tau is
found as aggregated abnormal ﬁlaments, such as neuroﬁbrillary tangles
within the brains of tauopathic patients. These insoluble tau portions
are localized in the somatodendritic compartments of cells, in contrast
to their usual localization in axons. Tangles have different distributions
and ultrastructural morphologies in the brain according to speciﬁc
tauopathies and speciﬁc disease-causing mutations. For instance, AD
neuroﬁbrillary tangles consist of paired helical ﬁlaments. Patients with
PSP and FTDP-17 and mutations in exon 10 have neuroﬁbrillary tangles
with straight tau ﬁlaments (Kambe et al., 2011). Unfortunately, there is
no currently available treatment to improve the prognosis of any of
these progressive diseases. Consequently, researchers are aiming at de-
termination of the underlying pathophysiology of tauopathies, in order
to isolate novel therapeutic agents that prevent disease progression
(Ludolph et al., 2009). It is noteworthy that accumulation of tauoligomers results inmitochondrial dysfunctionwith learning andmem-
ory impairment (Huang et al., 2006; Zhang et al., 2006).
2.1. Mitochondrial complex-I and taupathies
Mitochondrial dysfunction is thought to play an important role in
the development of tau pathology (Kulic et al., 2009). Mitochondrial
complex-I is a group of eukaryotic intracellular organelles, which utilize
the cells' energy. Inside the mitochondria, the oxidative phosphoryla-
tion (OXPHOS) pathway harvests the energy into nutrients and trans-
forms it into adenosine triphosphate (ATP) (Wanrooij and Falkenberg,
2010). Hence, mitochondrial dysfunction leads to impairment in energy
metabolism and oxidative stress, effects that are linked to aging pro-
cesses and many age-related neurodegenerative conditions (Gibson
et al., 2010). The OXPHOS system, which is embedded in the lipid bilay-
er of the mitochondrial inner membrane, is the ﬁnal biochemical path-
way in the energy production of the cell (Janssen et al., 2004). This
system consists of ﬁve enzyme complexes with two mobile electron
carriers. NADH: Ubiquinone oxidoreductase (complex I) the ﬁrst and
the largest of the ﬁve complexes is one of the two entry points of the
OXPHOS system (complex II being the other). It initiates electron trans-
fer by oxidizing NADH and using the lipid soluble ubiquinone as the
electron acceptor (Valsecchi et al., 2009). Complex I (CI) consists of 45
different subunits; seven of them are encoded by the mitochondrial
DNA (mtDNA), while the nuclear DNA (nDNA) encodes the remainder.
In addition, proper assembly of functional CI requires the assistance of
what is called assembly factors. These are several proteins that are in-
volved in the assembly of CI but are not part of the ﬁnal structure of
the enzyme. Identiﬁcation of these assembly factors opens a new ﬁeld
of possible pathways leading to CI deﬁciency (Willems et al., 2009).
NDUFA12L appears to be important for the correct assembly and
function of a multi-protein complex implicated in the energy produc-
tion of cells. Presently, the biological consequences of NDUFA12L dele-
tions are not known. At least 6 factors (NDUFAF1/CIA30, NDUFAF2/
NDUFA12L/B17.2L/Mimetin, C6orf66/HRPAP20, C8orf38, C20orf7 and
Ecsit) have been identiﬁed so far. Mutations in assembly factors reduce
the amount of fully assembled functional complex by affecting the rate
of CI stability. A mutation in exon 2 of the gene encoding NDUFA12L
resulting in a premature stop codonwas identiﬁed in a patientwith pro-
gressive encephalopathy. The patient presented with severe enzymatic
deﬁciency of complex I that also correlated with reduced assembly of
the enzyme. Furthermore, given that NDUFA12Lwas shown to associate
with complex I subunits ND1, NDUFS1, NDUFS2 and NDUFS7 and Cure
PSP Genetics Consortium has now found an abnormal heterozygous ab-
sence (deletion) of the gene NDUFA12L in association with individual
patients with PSP, which represents one of the major tauopathy publi-
cations in preparation. NDUFS4 in normal mitochondria, it seems to
play a direct role in CI assembly (Lazarou et al., 2009). In another
study, in two clinical cases with mutation in the same assembly factor,
NDUFA12L, the activity of CI was reduced. This was accompanied by
involvement of the mamillothalamic tracts, substantia nigra/medial
lemniscus, medial longitudinal fasciculus, the corpus medullare and
the cerebellum (Barghuti et al., 2008). Detailed knowledge of the
cytopathological consequences of CI deﬁciency is prerequisite to under-
standing the clinical presentations and their heterogeneity, and
developing therapeutic strategies (Distelmaier et al., 2009). There are
epidemiological (Lannuzel et al., 2007), biochemical (Albers et al.,
2000, 2001; Swerdlow et al., 2000), MR-spectroscopical (Stamelou
et al., 2009), experimental (Hoglinger et al., 2005; Escobar-Khondiker
et al., 2007; Höllerhage et al., 2009), and clinical (Stamelou et al.,
2008) evidence suggesting that CI dysfunctionmight be functionally in-
volved in the pathogenesis of the taupathy PSP. Particularly, previous
data showed that accumulation of hyperphosphorylated tau occurs in
the somatodendritic compartment in neurons after administration of
neurotoxins, acting as CI inhibitors (Escobar-Khondiker et al., 2007;
Höllerhage et al., 2009). Thus, a potential functional impact ofmutations
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sis of tauopathies seemsan attractive hypothesis that needs to be tested.
However, at present, no data about the biochemical, pathological or
clinical consequence of NDUFA12L deletions are available.
3. Conclusions and future directions
There is no doubt that tau oligomers and taupathies are becoming an
extremely important endeavor in neurodegenerative disease research.
Thus, a better understanding of the deleterious effects of tau oligomers
on the brainwith a focus on themitochondrial complex, will likely to be
of great importance to solve themystery of the underlying pathology of
neurodegenerative disorders and other taupathies. As can be seen,
NDUFA12L has an important role for homeostasis of CI, thus affecting
OXPHOS and mitochondria, which play a critical role in neurodegener-
ative disorder pathogenesis. Based on that, polymorphism in this as-
sembly factor may pose a risk for developing such disorders. In brief,
screening for NDUFA12L dysfunctionmay identify risk group for neuro-
degenerationwith further opportunity of early intervention. Transgenic
models are available to test and validate the aforementioned link,which
may accelerate the discovery of more effective therapies for neurode-
generative taupathies and related disorders.
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